
Paulo G. Kotze
@pakotze
Life's a gas! Crohn's and Colitis my mission. Colorectal surgery unit - Catholic university of Parana.
ID: 164878826
http://lattes.cnpq.br/3666549932136698 10-07-2010 00:36:06
17,17K Tweet
2,2K Followers
796 Following

🔍 New narrative review from Robin Phillips FRU, St Mark's explores the evolution of classification systems for perianal Crohn’s disease — including the Official TOpClass Consortium classification - and highlights key knowledge gaps. 📖 Read here: rdcu.be/enQcd Techniques in Coloproctology Journal #IBD #Crohns

Robin Phillips FRU, St Mark's Official TOpClass Consortium Techniques in Coloproctology Journal Thanks to co-authors Easan Anand Eathar Shakweh Shivani Joshi Phil Tozer Ailsa Hart Luke Hanna Phillip Lung, as well as Tech Coloproctol Guest Editor Paulo G. Kotze




Patients with Crohn’s Disease and Ileostomy Can Respond to Upadacitinib | Digestive Diseases and Sciences Lauren Loeb, MD Jami Kinnucan, MD, FACG, AGAF, FCCF Jami Kinnucan, MD, FACG, AGAF, FCCF Jana G Hashash, MD, MSc Francis (Frank) Farraye, MD, MSc link.springer.com/article/10.100…

New! ACG Clinical Guideline Update on Ulcerative Colitis Rubin, et al. 📕 bit.ly/acg-uc-2025 Jasmohan Bajaj Millie Long David T. Rubin, MD Corey Siegel Edward Barnes MD MPH #IBD



Estuchando al 1 Fernando Gomollón en su clase introductoria del curso GADECCU para manejo clinico-quirurgico de EII en Cx Colorrectal Colaborativa LATAM . Clase verdaderamente magistral, supera ampliamente mis expectativas, que ya eran altas de por sí. Si no te inscribiste, todavia hay tiempo:





New The Lancet - Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3) thelancet.com/journals/lance… #GITwitter #MedTwitter


📖 Acute Severe Ulcerative #Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints 🔗 Read more at: ow.ly/cBGq50WpcXO Sailish Honap Laurent Peyrin-Biroulet Vipul Jairath MBChB DPhil Bruce E. Sands Parambir Dulai Paulo G. Kotze Silvio Danese


GALAXI 2/3 just published in The Lancet . Guselkumab superior to placebo and ustekinumab across multiple endpoints in mod-dev CD. The rigor of the trial design highlights how IBD trials need to be done to move the field forward. Bruce E. Sands David T. Rubin, MD thelancet.com/journals/lance…


